![]() | ![]() |
Formats:
|
||||||||||||||||||||
KRAB zinc-finger proteins localise to novel KAP1-containing foci that are
adjacent to PML nuclear bodies MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK ‡
Author for correspondence (e-mail:
h.sutherland/at/hgu.mrc.ac.uk)
*These authors contributed equally to this work Accepted November 19, 2008. This article has been cited by other articles in PMC.Summary The KRAB-zinc finger proteins (KRAB-ZFPs) represent a very large, but
poorly understood, family of transcriptional regulators in mammals. They are
thought to repress transcription via their interaction with KRAB-associated
protein 1 (KAP1), which then assembles a complex of chromatin modifiers to lay
down histone marks that are associated with inactive chromatin. Studies of
KRAB-ZFP/KAP1-mediated gene silencing, using reporter constructs and
ectopically expressed proteins, have shown colocalisation of both KAP1 and
repressed reporter target genes to domains of constitutive heterochromatin in
the nucleus. However, we show here that although KAP1 does indeed become
recruited to pericentric heterochromatin during differentiation of mouse
embryonic stem (ES) cells, endogenous KRAB-ZFPs do not. Rather, KRAB-ZFPs and
KAP1 relocalise to novel nucleoplasmic foci that we have termed KRAB- and
KAP1-associated (KAKA) foci. HP1s can also concentrate in these foci and there
is a close spatial relationship between KAKA nuclear foci and PML nuclear
bodies. Finally, we reveal differential requirements for the recruitment of
KAP1 to pericentric heterochromatin and KAKA foci, and suggest that KAKA foci
may contain sumoylated KAP1 – the form of the protein that is active in
transcriptional repression. Keywords: Chromatin, Heterochromatin, Histone methylation, HP1, Nuclear organisation, Transcriptional repression Introduction Zinc-finger proteins (ZFPs) that contain the Krüppel-associated box
(KRAB) domain comprise the largest single family of transcriptional regulators
in the mammalian genome (Huntley et al.,
2006; Ravasi et al.,
2003; Urrutia,
2003). The basis for their rapid evolution and expansion in
mammalian lineages (there are ~400 members in the human or mouse genomes),
as well as the target genes that they may regulate, remain poorly understood
(Krebs et al., 2005;
O'Geen et al., 2007).
KRAB-ZFPs are thought to repress transcription via interaction with
KRAB-associated protein 1 (KAP1)/TIF1β/TRIM28. In turn, KAP1 is thought
to function as a co-repressor by assembling a complex with HP1
(Ryan et al., 1999) and the
chromatin modifying enzymes: SETDB1 H3-K9 histone methyltransferase (HMTase)
(Schultz et al., 2002), NuRD
(Schultz et al., 2001) and
histone deacetylases (HDACs) (Nielsen et
al., 1999). Because of a paucity of known physiological targets of KRAB-ZFPs, most
progress towards understanding their mechanism of action has come from studies
using reporter genes. KRAB domains, which are tethered to a transgene, can
repress transcription via KAP1. KAP1 recruits SETDB1 and HP1α to a
region around the promoter, resulting in stable transgene silencing
(Ayyanathan et al., 2003). This
suggests that KRAB-ZFPs might repress gene expression by a localised
alteration of chromatin structure and H3K9 methylation. However, the silenced
reporter transgene was also seen to re-localise to domains of pericentromeric
heterochromatin in the nucleus, suggesting that KRAB-KAP1 repression mechanism
may also operate at the level of nuclear organisation. This latter idea is substantiated by reported changes in the subnuclear
distribution of KAP1. During the retinoic acid (RA)-induced differentiation of
F9 embryonal carcinoma (EC) and embryonic stem (ES) cells, KAP1 relocalises
from the nucleoplasm to the pericentromeric heterochromatin
(Cammas et al., 2002). It has
been suggested that this might also recruit target genes, and, by implication,
the KRAB-ZFPs, to these sites (Cammas et
al., 2004). Epitope-tagged KRAB-ZFPs have indeed been reported to
be concentrated at pericentromeric heterochromatin in some cells
(Matsuda et al., 2001);
(Payen et al., 1998;
Sutherland et al., 2001).
However, the subcellular localisation of endogenous KRAB-ZFP proteins has not
been extensively studied. Here, we have investigated the nuclear distribution of gene-trapped
KRAB-ZFPs during the RA-induced differentiation of embryonic stem (ES) cells.
We show that, upon differentiation, these fusion proteins, which all retain a
KRAB domain, but have lost their zinc fingers, are recruited to
pericentromeric heterochromatin in a KAP1-dependent manner. However, we show
that these gene-trapped KRAB-ZFPs are mislocalised. Endogenous KRAB-ZFPs,
Zfp647 and NT2 do not localise to the domains of pericentric heterochromatin,
but, rather, they locate at discrete foci in the nuclei of differentiated ES
cells, and these overlap with non-pericentromeric foci of KAP1 and with HP1
proteins. We have termed these KRAB and KAP1-associated (KAKA) foci. We demonstrate that, whereas the pericentromeric localisation of KAP1 is
dependent on trimethylation of H3-K9 that is catalysed by Suv39h1/h2, the
formation of KAKA foci is not. We also establish that there is close spatial
proximity between KAKA foci and PML-nuclear bodies (PML-NBs). We suggest that
KAKA foci represent a novel nuclear domain involved in the post-translational
modification of KRAB-ZFPs and KAP1 by sumoylation, and that they may also be
the sites of KRAB-ZFP-mediated gene silencing in the nucleus. Results Gene-trapped KRAB-ZFPs relocate to pericentric heterochromatin upon
differentiation We have previously described how a gene-trap screen (which uses an ATG- and
promoter-less gene-trap vector, and relies on in-frame splicing into an
endogenous gene transcript) can be used to identify proteins that reside in
different sub-nuclear compartments
(Sutherland et al., 2001). One
of the genes trapped in a continuation of this screen was Zfp647 in
the cell line ES492. Sequence analysis indicated that the protein encoded by
Zfp647 is a KRAB A+B family member
(Shannon et al., 2003), which
is separated by a linker region of 96 amino acids from 13
C2H2 zinc fingers. Although the majority of gene-traps
do integrate into introns, in the ES492 cell line the vector has inserted into
the 5′ end of the final ZF-encoding exon (after amino acid 147) of
Zfp647, and uses a cryptic splice donor. A schematic representation
of Zfp647 and the trapping of this locus, is shown in
Fig. 1A
To determine whether gene-trapped KRAB proteins do relocalise in the
nucleus upon differentiation, we used immunofluorescence with an antibody
(α-β-gal) that recognises the β-galactosidase (β-gal)
region of the gene-trapped KRAB proteins to analyse their nuclear distribution
before and after differentiation with retinoic acid (RA). Undifferentiated
cells were identified by co-immunofluorescence with an antibody that detects
stage-specific embryonic antigen-1 (SSEA-1) on the cell surface
(Matsui et al., 1992) [data
not shown]. In undifferentiated ES492 gene-trapped cells, the
Zfp647-β-gal fusion protein was found in fine speckles distributed across
the nucleus, but excluded from pericentric heterochromatin, and mostly
excluded from nucleoli (Fig.
1B This is reminiscent of the differentiation-dependent relocalisation of KAP1
to heterochromatin reported in EC and ES cells
(Cammas et al., 2002). To
determine whether KAP1 and KRAB-β-gal fusion proteins moved to
heterochromatin together, we analysed their subnuclear distribution by
co-immunofluorescence, both before and after RA-induced differentiation. In
undifferentiated ES cells, KAP1 also showed staining in fine speckles
distributed across the nucleus, but excluded from pericentric heterochromatin
and nucleoli, although no colocalisation with Zfp647-β-gal speckles was
detected (Fig. 1B Re-localisation of KRAB-ZFPs and KAP1 to heterochromatin after addition of
RA could result from differentiation per se, or from changes in the cell cycle
as rapidly dividing ES cells differentiate. Therefore, we analysed the
localisation of gene-trapped KRAB-ZFPs in BrdU pulse-labelled cells. Before
and after differentiaton, we could see KRAB-β-gal fusion proteins
concentrated at heterochromatin in both BrdU-positive and negative cells (data
not shown). Therefore, KRAB-ZFP movement to heterochromatin is not just a
consequence of withdrawal from the cell cycle. Localisation of GFP-tagged Zfp647 All of our gene-trapped KRAB-ZFPs retain the KAP1-interacting KRAB domain,
but lack the zinc fingers (ZFs) of the endogenous protein. As the ZFs probably
target the proteins to specific genes, or are responsible for interaction with
other proteins, the gene-trapped proteins may mislocalise relative to their
wild-type counterparts. We therefore generated constructs of GFP fused with
full-length Zfp647, as well as deletion constructs to investigate domains
responsible for subcellular localisation. A construct consisting of GFP fused to Zfp647 lacking the ZFs
(GFP-Zfp647ΔZF), thus similar to the gene-trapped protein, could
localise to pericentric heterochromatin cells
(Fig. 1C Generation of antibodies against endogenous Zfp647 The subnuclear localisation of GFP-tagged Zfp647 is generally consistent
with that of the gene-trapped KRAB-ZFPs, and with previous studies of KAP1
(Cammas et al., 2002), except
that the smaller foci seen with GFP-tagged protein were not apparent in the
gene-trapped cells. Therefore, we wished to examine the subcellular
localisation of endogenous Zfp647. We raised antibodies specific to amino
acids 90-174 in the linker region (broken line above linker of Zfp647 protein
diagrammed in Fig. 1A
Endogenous Zfp647 does not associate with pericentric
heterochromatin We examined the subcellular distribution of endogenous Zfp647 during ES
cell differentiation using our rabbit α-Zfp647 antibody. In
undifferentiated ES cells (–RA in
Fig. 3A
Colocalisation of KRAB-ZFPs and KAP1 defines a new nuclear body Co-staining of ES cells, with antibody that recognises KAP1, showed the
relocalisation of KAP1 to sites of constitutive heterochromatin upon
differentiation (Fig. 3A We tested whether similar foci exist in other cell types.
Non-heterochromatic foci containing both Zfp647 and KAP1 were also seen in the
nuclei of primary mouse embryonic fibroblasts (MEFs) from 12.5 dpc embryos
(Fig. 4A
KAKA foci also contain concentrations of HP1 KAP1 interacts, through its PxVxL motif, with HP1 proteins
(Nielsen et al., 1999;
Ryan et al., 1999) and this is
an integral part of the mechanism of transcriptional silencing mediated by
KRAB-ZFPs/KAP1(Ayyanathan et al.,
2003; Sripathy et al.,
2006). HP1α and β are concentrated at the domains of
heterochromatin where KAP1 is also colocalised
(Gilbert et al., 2003);
indeed, HP1 has been shown to be required for the localisation of KAP1 to
sites of constitutive heterochromatin during differentiation
(Cammas et al., 2002).
Interestingly, recent FRET data suggest differential interaction between KAP1
and different HP1 isoforms (Cammas et al.,
2007). However, as well as being located at domains of constitutive
heterochromatin (Fig. 5A
Another protein that can interact with KAP1 and contribute to
KRAB-ZFP-mediated transcriptional repression is the H3K9 histone
methyltransferase (HMTase) SETDB1
(Ayyanathan et al., 2003;
Schultz et al., 2002;
Sripathy et al., 2006). By
immunofluorescence, we observed that, although in some cells SETDB1
co-localises with KAP1 at pericentric heterochromatin (~40% of cells in
day 10 differentiated ES cells, data not shown), most of the protein appears
to be located in foci in the nucleoplasm
(Fig. 5C KAKA foci are often adjacent to PML nuclear bodies Our data suggest that KRAB-ZFPs and the KAP1/HP1 repression machinery
colocalise together at multiple nucleoplasmic foci that we have termed KAKA
foci. To determine whether these foci represent a novel nuclear
sub-compartment, we analysed their spatial relationship to other nuclear
bodies that have a superficial resemblance in size and number. First, co-staining with CREST antisera, which recognise centromere
components, revealed that KAKA foci are distinct from centromeres/kinetochores
(Fig. 6A
HP1s, together with MacroH2A, have been found to accumulate in
senescence-associated heterochromatin foci (SAHF)
(Zhang et al., 2005), but no
SAHF bodies were detected with an antibody that recognises MacroH2A during our
ES cell differentiation (data not shown). KAP1 is a member of the TRIM/RBCC (tripartite motif/Ring finger, B-box,
coiled-coil) family of proteins, many of which have been described as
localised to discrete cellular subcompartments
(Meroni and ez-Roux, 2005;
Reymond et al., 2001). A
prominent such example of an RBCC protein is PML – the principal
component and the organiser of PML nuclear bodies (PML-NBs). Co-staining of
differentiated ES cells with α-ZFP-647, and with antibody that
recognises PML and decorates PML-NBs, revealed that KAKA foci are not
coincident with PML-NBs. However, KAKA foci show a spatial relationship with
PML-NBs in the majority of the cells in which they are present (arrowed in
Fig. 6B PML was one of the first substrates identified that is subject to
modification by the small ubiquitin-like modifier (SUMO)
(Sternsdorf et al., 1997) and
both SUMOs, and the machinery involved in both the addition and removal of
SUMO from substrates, are found concentrated in PML-NBs
(Boddy et al., 1996)
(http://npd.hgu.mrc.ac.uk/index.html).
Indeed, we observed that KAKA foci were also indeed juxtaposed to PML-NBs
detected by antibodies that recognise either SUMO1 or SUMO2/3
(Fig. 6C,D Targeting of KAP1 to pericentric heterochromatin, but not to KAKA
foci, is dependent on Suv39h HMTases To understand the factors that contribute to the differential targeting of
KAP1, HP1 and KRAB-ZFPs to pericentric heterochromatin or to KAKA foci, we
took advantage of mouse ES cells that lack the factors responsible for
epigenetic marks characteristic of heterochromatin. The highest concentration
of methylated CpGs in mouse cells is at pericentric heterochromatin, and the
DNA methyltransferases (DNMTs) Dnmt3a and Dnmt3b also concentrate there
(Bachman et al., 2001). In the
absence of these DNMTs, and with the consequent loss of DNA methylation, there
is an altered nuclear organisation and histone modification profile at
pericentric heterochromatin (Gilbert et
al., 2007). Transgene studies have also implicated DNA methylation
and recruitment to domains of pericentric heterochromatin in the KRAB-mediated
repression mechanism (Ayyanathan et al.,
2003). However, in late passage
Dnmt3a/b–/– cells, which we have previously
shown have no detectable remaining CpG methylation
(Gilbert et al., 2007), we
found that KAP1 was still concentrated at heterochromatin (data not shown).
Therefore, DNA methylation at pericentromeric heterochromatin is not needed to
sequester KAP1 there. Another chromatin mark characteristic of pericentric heterochromatin is
tri-methylated H3-K9 (H3K9me3) laid down by the Suv39h family of HMTases. In
mouse cells null for both Suv39h1 and Suv39h2 (Suv39h
dn), the absence of H3K9me3 leads to a delocalisation of HP1α and
HP1β from pericentromeric heterochromatin
(Lehnertz et al., 2003)
(Fig. 7A
Sumoylation of KAP1 corresponds to the appearance of KAKA foci We also observed that both SUMO1 and SUMO2/3 could be found concentrated at
pericentric heterochromatin in some differentiated ES cells (SUMO1 shown in
Fig. 8A
The appearance of KAKA foci during ES cell differentiation, and their
proximity to SUMO-containing PML-NBs, prompted us to address whether
sumoylation of KAP1 is also regulated during differentiation. By western blot
with a KAP1 antibody, we analysed total cell extracts, prepared in the
presence of N-ethylmaleimide (NEM) to preserve SUMO modification,
from both undifferentiated (–RA) and day 10 differentiated (+RA)
wild-type ES cells (wt41). We found that the major unmodified form of KAP1
(Fig. 8B Discussion KRAB ZFPs have a dynamic nuclear localisation The initial studies of transgenes silenced by the KRAB-KAP1 repression
mechanism (Ayyanathan et al.,
2003), the KAP1 localisation studies during ES and EC cell
differentiation (Cammas et al.,
2002; Cammas et al.,
2004), and the subnuclear localisation of epitope-tagged KRAB-ZFPs
(Matsuda et al., 2001;
Payen et al., 1998;
Sutherland et al., 2001)
(Fig. 1 What is the explanation for the differential localisation of endogenous and
ectopically expressed KRAB-ZFPs? Ectopic expression of GFP-tagged Zfp647
deletion constructs show that it is the KRAB domain itself that is required
for localisation to heterochromatin (Fig.
2 Thus, caution must be exercised in interpreting the mechanism of
transcriptional repression when using ectopically expressed KRAB-ZFPs; it
remains unclear what the function of KAP1 is, if any, at constitutive
heterochromatin. Some KRAB proteins do consist of only a KRAB domain, e.g.
MIF1 (Nikulina et al., 2006),
and some are alternatively spliced to generate a KRAB-box only protein, e.g.
KRAB-O from the Zfp208 locus (Oh
et al., 2005). Therefore, it is possible that localisation at
pericentric heterochromatin is relevant to the function of a subset of KRAB
box-containing proteins. However, our finding that, in Suv39h dn ES
cells, KAP1 is completely delocalised from pericentric heterochromatin,
presumably as a consequence of HP1 delocalisation
(Fig. 7 KRAB ZFPs characterise a novel nuclear body In differentiated mouse cells, we found that two endogenous KRAB-ZFPs
(Zfp647 and NT2) were concentrated in nucleoplasmic foci that are not
associated with pericentric heterochromatin, but are tightly associated with
foci of KAP1 (Figs (Figs33 KAKA foci also contain the known KAP1-interacting proteins HP1α and
HP1β (Nielsen et al.,
1999; Ryan et al.,
1999). We also show that another component of the KAP1-mediated
repression machinery, SETDB1 (Schultz et
al., 2002), is present in nucleoplasmic foci that we observe
occasionally overlapping with KAKA foci
(Fig. 5C KAKA foci – twin of PML NBs? We have shown that KAKA foci are often juxtaposed to PML nuclear bodies
(Fig. 6B Intriguingly, given the spatial juxtaposition of KAKA foci and PML-NBs,
both KAP1 and PML are proteins of the RBCC family. Modification of PML by
sumoylation is known to be important for the formation of PML-NBs
(Zhong et al., 2000) and SUMOs
are concentrated in PML-NBs (Bernardi and
Pandolfi, 2007) (Fig.
6C,D It has been suggested that PML itself might be a SUMO E3 ligase, modifying
both itself and other targets (Bernardi and
Pandolfi, 2007; Quimby et al.,
2006). Similarly, KAP1 has also been shown to be an
intra-molecular SUMO E3 ligase (Ivanov et
al., 2007). As it is the SUMOylated form of KAP1 that recruits the
downstream effectors such as SETDB1 and NURD, this suggests that KAKA foci
might be sites for modification and/or assembly of the components of
KRAB-ZFP-mediated transcriptional repression
(Ivanov et al., 2007;
Li et al., 2007;
Mascle et al., 2007). It remains for bone fide target genes of KRAB-ZFPs, such as Zfp647, to be
identified in order to address whether target genes are recruited to KAKA foci
for their silencing or whether KAKA foci are storage, processing or assembly
sites for the proteins involved in KRAB-ZFP-mediated silencing. Materials and Methods Cell culture and differentiation Undifferentiated E14 wt, gene-trapped,
Dnmt3ab–/–
(Okano et al., 1999),
Suv39h1/h2–/–
(Peters et al., 2001) and OS25
(Billon et al., 2002) ES cells
were maintained on 0.1% gelatin-coated dishes in Glasgow's modified Eagle's
medium (GMEM) containing 10% foetal calf serum (FCS), non-essential amino
acids, 1 mM sodium pyruvate, 0.3 mg/ml L-glutamine, 0.1 mM 2-mercaptoethanol
and 1000 U/ml human recombinant LIF. Mouse NIH3T3 fibroblasts were maintained
in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS. 100 μg/ml hygromycin B was used to select for undifferentiated
(Oct4-expressing) OS25 cells. To induce their differentiation,
5×105 OS25 cells were plated in 25 cm2 flasks
(Costar) without LIF or hygromycin B for 1 day. The cells were maintained in
medium with 5×10–6 M RA for the next 4 days. For the
remaining length of differentiation (up to day 10), 2.5 μM gancyclovir was
also added to RA-containing medium to select against undifferentiated
(Oct4-expressing) cells (Billon et al.,
2002). Media was changed every second day and cells were replated
or seeded onto 4×10 cm2 gelatinised slides as necessary. All
other cell lines maintained and differentiated as above with RA, but with no
selection. DNA sequence analysis of ES492/Zfp647 5′ RACE was used to obtain ~800 bp of sequence information for
the ES492 gene-trap as previously described
(Sutherland et al., 2001).
Mouse genomic and EST databases were searched for sequence matches using the
BLAST algorithm
(http://www.ncbi.nih.gov/BLAST/
or
http://www.ensembl.org/).
This revealed 94% nucleotide identity with hypothetical mouse mRNA
(NM_172817), which encodes Zfp647 (NP_766405), the 535 amino acid
KRAB-ZFP. We subcloned and sequenced the full-length Zfp647 cDNA from EST BI656339
(IMAGE clone 5326813). Domains of the trapped proteins were examined using
InterProScan
(http://www.ebi.ac.uk/InterProScan/)
and the Simple Modular Architecture Research Tool (SMART)
(http://smart.embl-heidelberg.de/).
The KRAB box is of the A+B family (Shannon
et al., 2003), and a linker region of 96 amino acids separates the
KRAB domain from the 13 C2H2 zinc fingers (ZFs). The gene trap is inserted
into the final ZF-encoding exon (after amino acid 147) and uses a cryptic
splice donor
(http://npd.hgu.mrc.ac.uk/search.php?action=builddetails&geneid=1NP01271). Cell transfection Full-length Zfp647 cDNA, and versions lacking the ZFs, or the KRAB
box, were cloned from PCR products in frame into pEGFP-C1 or -N1 vectors
(Clontech). Zfp647 lacking the ZFs (GFP-Zfp647ΔZF) consisted of GFP
fused to amino acids 1 to 186 of Zfp647. Zfp647 without the KRAB box consisted
of GFP fused to amino acids 187 to 535
(Fig. 1C Bacterial fusion proteins and antibody production Products encoding amino acids 90-174 of Zfp647, covering most of the linker
region, were PCR amplified from IMAGE clone 5326813 using the primers
5′ACTGAATTCGGAAGTGACCACTCAGAATGC3′ and
5′TGAGCGGCCGCATAGGGTCTCTCAACAGTGGG3′. The PCR product was
subcloned into pGex-4T-1 (Amersham Biosciences), sequenced and transformed
into E. coli BL21-CodonPlus (DE3)RP cells (Stratagene). Bacterial
GST-ZFP647 linker fusion protein was induced with IPTG and purified on
glutathione-agarose (Sigma) before injection into rabbits and sheep
(Diagnostic Scotland). The same PCR product was cloned into pET32a (Novagen);
the His-tagged fusion protein was purified on a Ni-agarose column (HIS-Select
Nickel Affinity Gel, Sigma) and an affinity column was made by binding it to
CNBr-activated sepharose 4B (Amersham Biosciences). Antibodies recognising
Zfp647 (α-Zfp647) were affinity purified against the Zfp647 linker
affinity column and specificity was confirmed by western blotting against
His-tagged Zfp647 protein expressed in E. coli (data not shown). Subcellular fractionation and western blotting Protein extracts from 12.5 dpc embryos were prepared by homogenisation of
dissected limbs (where Zfp647 is expressed) in 2×SDS loading buffer and
boiling samples before loading. Whole-cell protein extracts were made by
overlaying cells with PBS, adding an equal volume of 2×SDS protein
loading buffer and boiling before loading. NEM was added to the loading at a
final concentration of 20 mM in the protein samples in which it was used. For
nuclear extracts, cells were washed in PBS and resuspended on ice in nuclei
extraction Buffer A [NBA, 5.5% sucrose (w/v in dH2O), 10 mM
Tris-HCl (pH 8), 85 mM KCl, 0.5 mM spermidine, 250 μM PMSF (phenyl methyl
sulfonyl fluoride), 0.2 mM EDTA]. An equal volume of NBA + 0.1% NP-40 [v/v]
was then added prior to pelleting at 500 g for 3 minutes at
4°C. Nuclei were washed with NBA and their concentration determined from
the A260. An equal volume of 2×SDS protein loading buffer was
added to the sample and boiled before loading on SDS-PAGE gels. Total cell,
cytoplasmic and nuclear NIH3T3 fractions were prepared as previously described
(Sutherland et al., 2004). For western blotting, protein extracts were fractionated by 10-12% SDS-PAGE
and transferred to a nylon membrane by wet blotting (GENIE blotter, Idea
Scientific). The membranes were incubated with primary antibodies and detected
by horseradish peroxidase (HRP)-conjugated donkey anti-rabbit or anti-mouse
whole molecule IgG (Sigma, 1:10,000) and chemiluminescence (SuperSignal
1:2000). Primary antibody dilutions were as follows: 1:1000 sheep α-647
(3.2 mg/ml), 1:1500 rabbit α-647 (4.75 mg/ml) and 1:2500 rabbit
α-KAP1 (Bethyl Laboratories, A300-274A). For loading controls, protein
extracts were stained with GelCode Blue stain reagent (ThermoScientific) after
fractionation. For histone loading controls, protein extracts were
fractionated by 17% SDS-PAGE before GelCode Blue staining. Immunofluorescence Cells were grown as monolayers on slides and fixed for 20 minutes in 3%
paraformaldehyde (pFa)/PBS containing 1.5 mM MgCl2 and 1 mM
CaCl2. Fix was quenched in 50 mM NH4Cl/PBS for 10
minutes and cells were permeabilised in 0.25% Triton X-100/PBS for 12 minutes.
Cells were incubated overnight with primary antibodies: 1:150 dilution of
rabbit α-647 (this paper); undiluted mAb supernatant recognising KAP1
(gift of F. J. Rauscher III and D. Schultz) or a 1:1200 dilution of a mAb
against KAP1 (gift of P. Chambon); 1:500 dilutions of mouse mAb
α-HP1α, β and γ (Chemicon); 1:200 dilution mouse mAb
α-SSEA-1 (DSHB); 1:2000 dilution of rabbit α-β-gal (Europa)
or a mAb against β-gal (Promega); 1:1000 dilution of mouse mAb
α-PML (Chemicon); 1:300 dilution of CREST sera
(Gilchrist et al., 2004);
1:150 dilution of sheep α-SUMO1 and 1:50 dilution of α-SUMO2/3
(gifts of Ron Hay); 1:200 dilution of MacroH2A1 (Upstate); and 1:500 dilution
of α-phospho-H2AX [Ser139] (Upstate). After washing off non-specifically
bound antibody, the slides were then incubated for 1 hour with 1:200 dilutions
of FITC- or TexasRed-labelled secondary antibodies (Jackson and Vector
Laboratories) or 1:1000 dilutions of Alexa Fluor 488 or Alexa Fluor 594
secondary antibodies (Invitrogen). For treatment with UV, cells were irradiated with 200 J/m2 of
UV-C at 254 nm (UV Stratalinker 1800, Stratagene), returned to media and
incubated for 30 minutes before fixation and immunofluorescence as described
above. For immunofluorescence combined with detection of bromodeoxyuridine
(BrdU) incorporation, 0.01 M BrdU (Roche) was added to cells in culture 30
minutes before fixation in 3% pFa for 20 minutes. Cells were incubated with
primary antibody and subsequently fixed in 10% formalin (v/v)/PBS for 10
minutes and permeabilised with 0.1% Triton X-100/PBS for 12 minutes. DNA was
denatured with a 30-minute 2 M HCl treatment to allow for α-BrdU
antibody access. Cells were washed in PBS, blocked for 10 minutes in 5% BSA
(w/v) before incubating with 1:100 dilution of a rabbit antibody recognising
BrdU (Harlan SeraLab) for 1 hour, followed by incubation with secondary
antibodies. Slides were counterstained with 0.5 μg/ml DAPI in Vectashield, and
examined on a Zeiss Axioplan epifluorescence microscope equipped with a triple
band-pass filter (Chroma #83000) and imaged with cooled CCD camera using IPLAB
software v. 3.6 (Scanlytics, USA). For optical sectioning, the microscope
objective was fitted with a Pifoc motor to allow optical sectioning in the
z-axis and the images were subject to deconvolution to remove out of
focus blur using Hazebuster deconvolution software. A Zeiss LSM510
laser-scanning confocal microscope was also used for examining some
slides. [Supplementary Material]
Notes S.B. and C.C. were funded by PhD studentships from the James
S. McDonnell Foundation and the UK Medical
Research Council, respectively. W.A.B. is
a Centennial fellow of the James S. McDonnell Foundation. H.G.S. was part
funded by the AICR. This work was supported by
the Medical Research
Council, UK and in part by the
EU FP6 Network of Excellence Epigenome
(LSHG-CT-2004-503433). We thank Phillipe Gautier for
bioinformatics assistance. We thank Frank Rauscher III (Wistar Institute,
Philadelphia) and D. Schultz (Case Western Reserve University, Cleveland) for
the KAP1 mAb; Pierre Chambon (IGBMC, University of Louis Pasteur, France) for
the mouse TIF1β mAb; Yoshihiko Yamada (Kyushu University, Japan) for the
NT2 antibody; and Ron Hay (Wellcome Trust Biocentre, University of Dundee) for
the SUMO1 and SUMO2/3 antibodies. En Li (Novartis Institutes for BioMedical
Research) and Thomas Jenuwein (IMP, Vienna) provided Dnmt3ab and Suv39h double
knockout ES cells, respectively. Deposited in PMC for release after 6
months. Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/122/7/937/DC1 References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Genome Res. 2006 May; 16(5):669-77.
[Genome Res. 2006]Genome Res. 2003 Jun; 13(6B):1430-42.
[Genome Res. 2003]Genome Biol. 2003; 4(10):231.
[Genome Biol. 2003]Genomics. 2005 Jun; 85(6):752-61.
[Genomics. 2005]PLoS Genet. 2007 Jun; 3(6):e89.
[PLoS Genet. 2007]Genes Dev. 2003 Aug 1; 17(15):1855-69.
[Genes Dev. 2003]J Cell Sci. 2002 Sep 1; 115(Pt 17):3439-48.
[J Cell Sci. 2002]Genes Dev. 2004 Sep 1; 18(17):2147-60.
[Genes Dev. 2004]J Biol Chem. 2001 Apr 27; 276(17):14222-9.
[J Biol Chem. 2001]J Biol Chem. 1998 Apr 10; 273(15):9099-109.
[J Biol Chem. 1998]Hum Mol Genet. 2001 Sep 1; 10(18):1995-2011.
[Hum Mol Genet. 2001]Hum Mol Genet. 2001 Sep 1; 10(18):1995-2011.
[Hum Mol Genet. 2001]Genome Res. 2003 Jun; 13(6A):1097-110.
[Genome Res. 2003]Cell. 1992 Sep 4; 70(5):841-7.
[Cell. 1992]Hum Mol Genet. 2001 Sep 1; 10(18):1995-2011.
[Hum Mol Genet. 2001]J Cell Sci. 2002 Sep 1; 115(Pt 17):3439-48.
[J Cell Sci. 2002]J Biol Chem. 2001 Apr 27; 276(17):14222-9.
[J Biol Chem. 2001]J Cell Sci. 2002 Sep 1; 115(Pt 17):3439-48.
[J Cell Sci. 2002]J Cell Sci. 2002 Sep 1; 115(Pt 17):3439-48.
[J Cell Sci. 2002]Mol Cell Biol. 2002 Jun; 22(12):4256-67.
[Mol Cell Biol. 2002]EMBO J. 1999 Nov 15; 18(22):6385-95.
[EMBO J. 1999]Mol Cell Biol. 1999 Jun; 19(6):4366-78.
[Mol Cell Biol. 1999]Genes Dev. 2003 Aug 1; 17(15):1855-69.
[Genes Dev. 2003]Mol Cell Biol. 2006 Nov; 26(22):8623-38.
[Mol Cell Biol. 2006]EMBO J. 2003 Oct 15; 22(20):5540-50.
[EMBO J. 2003]Genes Dev. 2003 Aug 1; 17(15):1855-69.
[Genes Dev. 2003]Genes Dev. 2002 Apr 15; 16(8):919-32.
[Genes Dev. 2002]Mol Cell Biol. 2006 Nov; 26(22):8623-38.
[Mol Cell Biol. 2006]Cancer Res. 2006 Dec 15; 66(24):11594-9.
[Cancer Res. 2006]Dev Cell. 2005 Jan; 8(1):19-30.
[Dev Cell. 2005]Bioessays. 2005 Nov; 27(11):1147-57.
[Bioessays. 2005]EMBO J. 2001 May 1; 20(9):2140-51.
[EMBO J. 2001]J Cell Biol. 1997 Dec 29; 139(7):1621-34.
[J Cell Biol. 1997]Oncogene. 1996 Sep 5; 13(5):971-82.
[Oncogene. 1996]J Biol Chem. 2001 Aug 24; 276(34):32282-7.
[J Biol Chem. 2001]J Cell Biol. 2007 May 7; 177(3):401-11.
[J Cell Biol. 2007]Genes Dev. 2003 Aug 1; 17(15):1855-69.
[Genes Dev. 2003]Curr Biol. 2003 Jul 15; 13(14):1192-200.
[Curr Biol. 2003]Mol Cell. 2007 Dec 14; 28(5):823-37.
[Mol Cell. 2007]J Biol Chem. 2007 Jan 19; 282(3):1595-606.
[J Biol Chem. 2007]J Biol Chem. 2007 Dec 14; 282(50):36177-89.
[J Biol Chem. 2007]J Biol Chem. 2007 Apr 6; 282(14):10190-202.
[J Biol Chem. 2007]Genes Dev. 2004 Sep 1; 18(17):2147-60.
[Genes Dev. 2004]Mol Cell. 2007 Dec 14; 28(5):823-37.
[Mol Cell. 2007]J Biol Chem. 2007 Jan 19; 282(3):1595-606.
[J Biol Chem. 2007]J Biol Chem. 2007 Dec 14; 282(50):36177-89.
[J Biol Chem. 2007]J Biol Chem. 2007 Apr 6; 282(14):10190-202.
[J Biol Chem. 2007]Genes Dev. 2003 Aug 1; 17(15):1855-69.
[Genes Dev. 2003]J Cell Sci. 2002 Sep 1; 115(Pt 17):3439-48.
[J Cell Sci. 2002]Genes Dev. 2004 Sep 1; 18(17):2147-60.
[Genes Dev. 2004]J Biol Chem. 2001 Apr 27; 276(17):14222-9.
[J Biol Chem. 2001]J Biol Chem. 1998 Apr 10; 273(15):9099-109.
[J Biol Chem. 1998]Genes Dev. 1996 Aug 15; 10(16):2067-78.
[Genes Dev. 1996]J Biol Chem. 2001 Apr 27; 276(17):14222-9.
[J Biol Chem. 2001]Biochem Biophys Res Commun. 2006 Sep 29; 348(3):839-49.
[Biochem Biophys Res Commun. 2006]Biol Reprod. 2005 Feb; 72(2):407-15.
[Biol Reprod. 2005]Cell. 2001 Nov 2; 107(3):323-37.
[Cell. 2001]Development. 2000 Jul; 127(13):2955-63.
[Development. 2000]Mol Cell. 2007 Dec 14; 28(5):823-37.
[Mol Cell. 2007]Exp Cell Res. 2006 Apr 1; 312(6):901-12.
[Exp Cell Res. 2006]EMBO J. 1999 Nov 15; 18(22):6385-95.
[EMBO J. 1999]Mol Cell Biol. 1999 Jun; 19(6):4366-78.
[Mol Cell Biol. 1999]Genes Dev. 2002 Apr 15; 16(8):919-32.
[Genes Dev. 2002]PLoS Genet. 2007 Jun; 3(6):e89.
[PLoS Genet. 2007]Mol Biol Cell. 2006 Mar; 17(3):1126-40.
[Mol Biol Cell. 2006]Blood. 2000 May 1; 95(9):2748-52.
[Blood. 2000]Nat Rev Mol Cell Biol. 2007 Dec; 8(12):1006-16.
[Nat Rev Mol Cell Biol. 2007]Mol Cell Proteomics. 2006 Dec; 5(12):2298-310.
[Mol Cell Proteomics. 2006]Nat Rev Mol Cell Biol. 2007 Dec; 8(12):1006-16.
[Nat Rev Mol Cell Biol. 2007]Oncogene. 2006 May 18; 25(21):2999-3005.
[Oncogene. 2006]Mol Cell. 2007 Dec 14; 28(5):823-37.
[Mol Cell. 2007]J Biol Chem. 2007 Dec 14; 282(50):36177-89.
[J Biol Chem. 2007]J Biol Chem. 2007 Apr 6; 282(14):10190-202.
[J Biol Chem. 2007]Cell. 1999 Oct 29; 99(3):247-57.
[Cell. 1999]Cell. 2001 Nov 2; 107(3):323-37.
[Cell. 2001]J Cell Sci. 2002 Sep 15; 115(Pt 18):3657-65.
[J Cell Sci. 2002]J Cell Sci. 2002 Sep 15; 115(Pt 18):3657-65.
[J Cell Sci. 2002]Hum Mol Genet. 2001 Sep 1; 10(18):1995-2011.
[Hum Mol Genet. 2001]Genome Res. 2003 Jun; 13(6A):1097-110.
[Genome Res. 2003]Exp Cell Res. 2004 Mar 10; 294(1):94-105.
[Exp Cell Res. 2004]Chromosome Res. 2004; 12(5):505-16.
[Chromosome Res. 2004]